Pacira BioSciences (PCRX) Total Non-Current Liabilities (2010 - 2026)

Pacira BioSciences' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $530.0 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 30.65% year-over-year to $530.0 million in Q1 2026; TTM through Mar 2026 was $530.0 million, a 30.65% decrease from a year earlier, with the FY2025 full-year figure at $551.2 million, down 27.31% from the prior year.
• Total Non-Current Liabilities declined to $530.0 million in Q1 2026 per PCRX's latest filing, from $551.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $1.2 billion in Q1 2022 and bottomed at $530.0 million in Q1 2026.
• The 5-year median for Total Non-Current Liabilities is $754.3 million (2025), against an average of $759.7 million.
• Across the five-year window, Total Non-Current Liabilities soared 85.48% in 2022 and plunged 36.49% in 2023, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $896.5 million in 2022, then dropped by 22.96% to $690.7 million in 2023, then advanced by 9.8% to $758.4 million in 2024, then decreased by 27.31% to $551.2 million in 2025, then slipped by 3.85% to $530.0 million in 2026.
• Per Business Quant, the three latest PCRX Total Non-Current Liabilities figures stand at $530.0 million (Q1 2026), $551.2 million (Q4 2025), and $545.1 million (Q3 2025).